Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J1413 Injection delandistrogene mox rokl

J Codes (Drugs)

Also known as: delandistrogene moxeparvovec, SMA gene therapy

Delandistrogene moxeparvovec injection. A gene therapy for spinal muscular atrophy type 1 administered intravenously.

In Plain Language

spinal muscular atrophy treatment; genetic muscle disease therapy

Clinical Context

Used for spinal muscular atrophy type 1 (SMA1), a severe genetic neuromuscular disease in infants. Gene therapy designed to restore SMN protein production. Single-dose therapy with potential for sustained benefit.

RVU Information

CPT J1413 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

GeneticsNeurologyPediatrics

Frequently Asked Questions

What is CPT code J1413?

CPT J1413 (Injection delandistrogene mox rokl) is a J Codes (Drugs) code. Delandistrogene moxeparvovec injection. A gene therapy for spinal muscular atrophy type 1 administered intravenously.

How is J1413 administered?

CPT J1413 is administered by a healthcare provider, typically via injection or infusion. Used for spinal muscular atrophy type 1 (SMA1), a severe genetic neuromuscular disease in infants. Gene therapy designed to restore SMN protein production. Single-dose therapy with potential for sustained benefit. It is used by Genetics, Neurology, Pediatrics.

When is CPT J1413 used?

Used for spinal muscular atrophy type 1 (SMA1), a severe genetic neuromuscular disease in infants. Gene therapy designed to restore SMN protein production. Single-dose therapy with potential for sustained benefit.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.